ArticleeGastroenterology2026
Exercise and dietary interventions ameliorate MASLD via the hepatic PPARγ-miR-802-Psmd2 axis.
Article in eGastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: MicroRNAs critically regulate metabolic dysfunction-associated steatotic liver disease (MASLD) progression and intervention. Lifestyle modifications, particularly exercise and time-restricted feeding (TRF), emerge as effective non-pharmacological strategies. Methods: MiR-802 expression was quantified in plasma exosomes and hepatic tissues of MASLD mouse models using quantitative PCR and sequencing. In vivo and in vitro gain-of-function and loss-of-function experiments assessed its regulatory effects on hepatic lipotoxicity, complemented by bioinformatic predictions and luciferase-based validation of upstream transcription factors and downstream targets. Functional crosstalk between miR-802 and its regulatory network was examined under lipotoxic conditions. Therapeutic interventions, including exercise and TRF, were implemented in high-fat diet fed mice, with subsequent evaluation of miR-802 expression dynamics. Results: Here, we show elevated miR-802 levels in plasma exosomes and livers of MASLD mice, with its inhibition reducing hepatocyte lipotoxicity. Mechanistically, peroxisome proliferator-activated receptor gamma (PPARγ) promotes miR-802 transcription, whereas miR-802 suppresses the proteasome 26S subunit ubiquitin receptor, non-ATPase 2 (Psmd2). Genetic and pharmacological modulation of PPARγ downregulates miR-802 and ameliorates MASLD. Notably, both exercise and TRF reduce hepatic PPARγ and miR-802 expression and improve MASLD via the PPARγ-miR-802-Psmd2 axis, revealing lifestyle modification-mediated epigenetic regulation in MASLD pathophysiology. Conclusion: This study reveals the PPARγ-miR-802-Psmd2 axis as a central regulatory mechanism in MASLD pathogenesis and innovatively links lifestyle interventions (exercise and TRF) to therapeutic effects via this pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.